Pancreatic Cancer: Early Detection and Treatment Gaps | Market Intelligence

Description

List of Tables

Pancreatic cancer is the report card Japan's cancer system would rather not publish. The annual case count and the annual death count sit almost on top of each other - a mortality-to-incidence relationship no other major cancer matches - because most patients arrive with disease already spread, and the treatments available change that arithmetic only marginally. Surgery remains the only curative route, yet the window in which surgery is possible closes before symptoms force a diagnosis in the great majority of cases. Every serious analysis of the disease converges on the same conclusion: the leverage is in finding it earlier, and in the KRAS biology that drives nearly all of it.

The tension is that both levers are immature in instructive ways. Early detection lacks a proven screening target population and a validated test: multi-cancer blood tests from GRAIL, Freenome, Exact Sciences, Delfi, and Immunovia carry pancreatic signal claims of varying maturity, Japan's own Craif pursues a urine miRNA approach, and none yet has a reimbursement route or a defined high-risk pathway to attach to. On treatment, gemcitabine-based backbones and FOLFIRINOX define a standard that has barely moved, while Revolution Medicines' daraxonrasib pivotal program tests whether RAS(ON) inhibition can finally crack the disease's core driver - with Lilly, Verastem, and radioligand interests arrayed behind. What Japan's payer will fund, and against what evidence, is undecided on both fronts.

This report maps pancreatic cancer in Japan across the full chain: epidemiology and risk factors, the diagnostic pathway and its delays, surgical and systemic standards, the KRAS-directed pipeline program by program, and the early-detection field test by test. It treats the high-risk surveillance question - new-onset diabetes, family history, intraductal papillary mucinous neoplasm follow-up - as a defined commercial and clinical segment, and examines where Japanese diagnostics capability could attach to global early-detection platforms.

The report serves diagnostics investors evaluating early-detection claims, biotech BD teams tracking KRAS and pancreatic pipelines, hospital planners, and payers preparing for either a screening test or a practice-changing therapy. It is organized so that each reader can locate the specific uncertainty - validation, regulation, reimbursement, or sequencing - that governs their decision.

Scope and Coverage: The report covers pancreatic cancer epidemiology, diagnostic pathways, surgical and systemic treatment standards, KRAS-directed and other pipeline therapies, and the early-detection test landscape as each applies to Japan. It profiles Revolution Medicines, Lilly, Novartis, Verastem, GRAIL, Freenome, Exact Sciences, Delfi, Immunovia, Craif, and Burning Rock.

Report Highlights:

Quantifies the framework of Japan's pancreatic mortality-incidence relationship and diagnostic-delay structure
Maps the treatment standard: surgery, FOLFIRINOX, gemcitabine-nab-paclitaxel, and maintenance options
Profiles the KRAS-directed pipeline led by daraxonrasib's pivotal program
Reviews multi-cancer and pancreatic-specific early-detection tests and their evidence maturity
Defines the high-risk surveillance segment: new-onset diabetes, IPMN, and family history
Analyzes reimbursement and regulatory pathways for both diagnostics and therapeutics

Product Code: JPH-036

Table of Content

1. Executive Summary

2. Pancreatic Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Revolution Medicines (US) - daraxonrasib (RMC-6236) Phase 3 in pancreatic cancer
Eli Lilly (US) - KRAS and pancreatic cancer pipeline
Novartis (CH) - radioligand and targeted oncology portfolio relevant to pancreatic NETs
GRAIL (US) - Galleri multi-cancer early-detection test with pancreatic signal
Freenome (US) - blood-based multi-cancer early detection including pancreatic
Exact Sciences (US) - blood-based early-detection programs
Verastem (US) - avutometinib RAS/MAPK pathway program
Immunovia (SE) - IMMray PanCan-d pancreatic early-detection test
Delfi Diagnostics (US) - fragmentomics-based early detection
Craif (JP) - urine miRNA cancer detection including pancreatic
Burning Rock (CN) - multi-cancer early detection in China

Product Code: JPH-036

List of Tables

Table 1. Pancreatic Cancer Epidemiology in Japan: Registry Framework and Data Sources
Table 2. Mortality-to-Incidence Relationship: Structural Explanation Framework
Table 3. Risk Factor Map: Smoking, Diabetes, Chronic Pancreatitis, and Family History
Table 4. Diagnostic Pathway of Pancreatic Cancer in Japan: Referral and Delay Points
Table 5. Imaging Standards: CT, EUS, and MRI/MRCP Roles in Diagnosis
Table 6. CA19-9 and Established Biomarkers: Roles and Limitations
Table 7. Resectability Classification and Surgical Standards in Japan
Table 8. Pancreatic Surgery Center Concentration and Volume Standards
Table 9. Perioperative Regimens: Neoadjuvant and Adjuvant Frameworks
Table 10. FOLFIRINOX and Gemcitabine-Nab-Paclitaxel: First-Line Standards
Table 11. NALIRIFOX and NAPOLI-3 Program Context
Table 12. Maintenance and Second-Line Treatment Framework
Table 13. BRCA and Homologous-Recombination Alterations: Olaparib POLO Context
Table 14. MSI and Rare-Alteration Subgroups in Pancreatic Cancer
Table 15. KRAS Biology in Pancreatic Cancer: Allele Distribution
Table 16. Daraxonrasib (RMC-6236): Mechanism and Early-Phase Pancreatic Data Framework
Table 17. RASolute 302: Pivotal Program Design and Japanese Site Participation
Table 18. Revolution Medicines Allele-Selective Programs Relevant to Pancreas
Table 19. Lilly KRAS and Pancreatic Pipeline Programs
Table 20. Verastem Avutometinib RAS/MAPK Pathway Program
Table 21. Novartis Radioligand Relevance to Pancreatic Neuroendocrine Tumors
Table 22. Stroma-Targeting and Microenvironment Strategies: Program Landscape
Table 23. Immunotherapy Failure Modes in Pancreatic Cancer: Evidence Framework
Table 24. Early-Detection Concept Taxonomy: Single-Cancer vs Multi-Cancer Approaches
Table 25. GRAIL Galleri: Pancreatic Signal and Program Design
Table 26. Freenome Blood-Based Multi-Cancer Early-Detection Programs
Table 27. Exact Sciences Blood-Based Early-Detection Development
Table 28. Immunovia IMMray PanCan-d: Pancreatic-Specific Test Design
Table 29. Delfi Diagnostics Fragmentomics Platform
Table 30. Craif Urine miRNA Cancer Detection: Japanese Program Profile
Table 31. Burning Rock Multi-Cancer Early Detection: China Context
Table 32. Evidence Maturity Framework for Early-Detection Tests
Table 33. High-Risk Surveillance Segment: New-Onset Diabetes Enrichment Strategies
Table 34. IPMN and Cystic Lesion Follow-Up as a Surveillance Channel
Table 35. Familial and Genetic High-Risk Clinic Models
Table 36. Pancreatic NET Diagnostics and Treatment: Distinct Framework
Table 37. Regulatory Pathways for Early-Detection Tests in Japan
Table 38. Reimbursement Precedents for Cancer Screening Diagnostics Under NHI
Table 39. Pricing and Access Framework for Pancreatic Therapeutics
Table 40. Competitive Positioning Matrix: Pancreatic Pipeline Assets
Table 41. Deal Benchmarks for Pancreatic Oncology and Detection Licensing
Table 42. Trial-Enrollment Dynamics in Japanese Pancreatic Studies
Table 43. Scenario Framework: Early Detection Adoption vs Therapeutic Breakthrough Paths
Table 44. Risk Register: Validation Failure, Overdiagnosis, and Sequencing Disputes
Table 45. Indicator Dashboard for Pancreatic Theme Monitoring
Table 46. Due-Diligence Checklist for Early-Detection Investments
Table 47. Stakeholder Position Map: Societies, Payers, Developers, and Registries
Table 48. Real-World Data Sources for Pancreatic Cancer in Japan
Table 49. Patient Journey from Symptom Onset to Treatment Decision
Table 50. Analytical Appendix: Registries, Trial Sources, and Test-Validation Literature

List of Figures

Figure 1. Pancreatic Cancer Epidemiological Framework
Figure 2. Mortality-Incidence Structure Diagram
Figure 3. Risk Factor Map
Figure 4. Diagnostic Pathway and Delay Point Diagram
Figure 5. Imaging Standard Roles in Diagnosis
Figure 6. Biomarker Role and Limitation Framework
Figure 7. Resectability Classification Diagram
Figure 8. Surgical Center Concentration Map Framework
Figure 9. Perioperative Regimen Timeline
Figure 10. First-Line Standard Comparison Framework
Figure 11. NAPOLI-3 Program Schematic
Figure 12. Maintenance and Second-Line Framework
Figure 13. POLO and Homologous-Recombination Context
Figure 14. Rare-Alteration Subgroup Map
Figure 15. KRAS Allele Distribution in Pancreatic Cancer
Figure 16. Daraxonrasib Mechanism Diagram
Figure 17. RASolute 302 Design Schematic
Figure 18. Revolution Medicines Allele-Selective Program Map
Figure 19. Lilly and Verastem Pancreatic Programs
Figure 20. NET Radioligand Context Diagram
Figure 21. Stroma-Targeting Strategy Landscape
Figure 22. Immunotherapy Failure Mode Framework
Figure 23. Early-Detection Concept Taxonomy
Figure 24. GRAIL Galleri Program Structure
Figure 25. Freenome and Exact Sciences Program Maps
Figure 26. IMMray PanCan-d Test Design Diagram
Figure 27. Delfi Fragmentomics Platform Schematic
Figure 28. Craif Urine miRNA Program Diagram
Figure 29. Burning Rock China Context Map
Figure 30. Evidence Maturity Framework for Early Detection
Figure 31. New-Onset Diabetes Enrichment Strategy Diagram
Figure 32. IPMN Surveillance Channel Flow
Figure 33. Familial High-Risk Clinic Model
Figure 34. Pancreatic NET Distinct Framework Map
Figure 35. Regulatory Pathway Map for Early-Detection Tests
Figure 36. NHI Screening Reimbursement Precedent Map
Figure 37. Pancreatic Therapeutic Pricing Framework
Figure 38. Competitive Positioning Map: Pipeline Assets
Figure 39. Licensing Deal Benchmark Framework
Figure 40. Enrollment Dynamics in Japanese Pancreatic Studies
Figure 41. Scenario Tree: Detection Adoption vs Therapeutic Breakthrough
Figure 42. Risk Map: Validation, Overdiagnosis, and Sequencing
Figure 43. Pancreatic Theme Monitoring Dashboard
Figure 44. Early-Detection Investment Due-Diligence Flow
Figure 45. Stakeholder Position Map
Figure 46. Real-World Data Source Map
Figure 47. Patient Journey Diagram from Symptoms to Treatment
Figure 48. Investor KPI Dashboard for the Pancreatic Theme
Figure 49. Synthesis: Where Pancreatic Leverage Actually Sits in Japan
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

Pancreatic Cancer: Early Detection and Treatment Gaps | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Pancreatic Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures